Details about Alison Pearce

Access statistics for papers by Alison Pearce.

Last updated 2024-03-09. Update your information in the RePEc Author Service.

Short-id: ppe859

Journal Articles

2024

1. Role Preferences in Medical Decision Making: Relevance and Implications for Health Preference Research
   The Patient: Patient-Centered Outcomes Research, 2024, 17, (1), 3-12

2023

2. Estimating Global Friction Periods for Economic Evaluation: A Case Study of Selected OECD Member Countries
   PharmacoEconomics, 2023, 41, (9), 1093-1101 View citations (1)
3. Projected Impact on Labour Productivity Costs of Cancer-Related Premature Mortality in Europe 2018–2040
   Applied Health Economics and Health Policy, 2023, 21, (6), 877-889

2022

4. Cost-Effectiveness of Constraint-Induced Movement Therapy Implementation in Neurorehabilitation: The ACTIveARM Project
   PharmacoEconomics - Open, 2022, 6, (3), 437-450

2021

5. Employer survey to estimate the productivity friction period
   The European Journal of Health Economics, 2021, 22, (2), 255-266
6. Health system costs and days in hospital for colorectal cancer patients in New South Wales, Australia
   PLOS ONE, 2021, 16, (11), 1-19
7. Investigating the Association Between Self-Reported Comorbid Anxiety and Depression and Health Service Use in Cancer Survivors
   PharmacoEconomics, 2021, 39, (6), 681-690
8. Respondent Understanding in Discrete Choice Experiments: A Scoping Review
   The Patient: Patient-Centered Outcomes Research, 2021, 14, (1), 17-53 View citations (5)

2020

9. Advances in the methodological approach to friction period estimation: A European perspective
   Social Science & Medicine, 2020, 264, (C)

2017

10. Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study
    PLOS ONE, 2017, 12, (10), 1-12

2015

11. Productivity Losses Associated with Head and Neck Cancer Using the Human Capital and Friction Cost Approaches
    Applied Health Economics and Health Policy, 2015, 13, (4), 359-367 View citations (6)

2013

12. Are the True Impacts of Adverse Events Considered in Economic Models of Antineoplastic Drugs? A Systematic Review
    Applied Health Economics and Health Policy, 2013, 11, (6), 619-637